SuperworthAlkermes plc. ALKS
- Market cap
- $7.3B
- PE
- 115×
- 3y median 16.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.4×
- EV/EBIT
- 69.6×
- Revenue, 12 months
- $1.7B
- +11% on a year ago
- Net margin
- 4.0%
- Free cash flow yield
- 3.0%
Alkermes plc. trades at 115× trailing earnings, pricier than 95% of the last ten years. Revenue was $1.7B over the last twelve months, up 11% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $380.9M+51% | $377.5M+24% | $350.4M+22% | $399.1M−35% | $378.1M−1% | $430M+14% | $306.5M−13% | $390.7M−2% | $394.2M+4% | $384.5M−11% | $392.9M+28% | $496M+27% | |
| Cost of revenue | $61.5M+22% | $70.1M+30% | $58.6M+1% | $61.5M−3% | $63.1M+3% | $62.1M−11% | $49.2M−16% | $49.5M−20% | $51.6M−18% | $46.2M−26% | $61.6M+25% | $98.1M+98% |
| Gross profit | $319.4M+58% | $307.3M+23% | $291.7M+27% | $337.7M−39% | $315M−1% | $367.9M+20% | $257.3M−12% | $341.2M+1% | $342.6M+9% | $338.3M−8% | $331.3M+29% | $397.9M+17% |
| R&D | $64.9M−35% | $73.9M−29% | $67.6M+6% | $59.6M−13% | $59.9M−8% | $58.2M−21% | $71.8M+6% | $77.4M+30% | $81.7M+37% | $93M+60% | $103.3M+44% | $112.9M+46% |
| SG&A | $156.4M+2% | $169.8M+8% | $179.7M+7% | $168.1M−14% | $150.4M−4% | $147M−13% | $171.7M−5% | $170.8M+2% | $171.8M+14% | $187.2M+27% | $264.6M+54% | $217.6M+27% |
| $89.2M | $54.6M | $43.3M | $109.9M−61% | $104.8M+17% | $162.7M+198% | $13.8M−68% | $93M−15% | $89.1M−15% | $58.1M−64% | −$48.3M | $18.4M−80% | |
| Interest expense | $6M+69% | $6.1M+27% | $6M+13% | $6M+5% | $6M−0% | $4.6M−23% | $0 | $0 | $0 | $12.3M+164% | $20.9M | $25.9M |
| Pre-tax income | $92.7M | $58.3M | $46.9M | $116.7M−59% | $110.2M+19% | $169.9M+191% | $25.5M−46% | $104.8M−10% | $100.7M−9% | $60.4M−65% | −$61.9M | −$1.9M |
| $1.2M | −$102.2M | $8M+1011% | $22.1M+709% | $17.4M+1412% | $24.2M | $3M−62% | $17.7M−20% | $18M+3% | $11M−54% | $4.6M+51% | −$2.4M | |
| Net income | $47.8M | $112.8M | $36.8M | $91.4M−62% | $92.4M+93% | $146.5M+30% | $22.5M−39% | $87.1M−5% | $82.8M−10% | $49.3M−66% | −$66.5M | $501K−99% |
| $0.28 | $0.68 | $0.21 | $0.53−62% | $0.55+96% | $0.88+29% | $0.13−38% | $0.52−2% | $0.49−11% | $0.29−67% | −$0.40 | $0.00 | |
| 171.9M+5% | 166M+2% | 173M+5% | 171M−0% | 167M−3% | 166.2M+0% | 168.7M−3% | 168.4M−2% | 168.5M+1% | 169.6M+2% | 166.2M−2% | 173.5M+3% |
Revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them. 63 periods, Q2 FY11 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them. 25 periods, Q1 FY13 to Q2 FY18: not printed by the filing, worked out from its own lines.
EPS, diluted: 15 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY12 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | 3.0× | +13% | 20.4% | |
| Peer median | $7.4B | 60.3× | 44.6× | 7.8× | +25% | 15.0% |
More on Alkermes plc.
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .